KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Asset Writedowns and Impairment: 2019-2024

Historic Asset Writedowns and Impairment for Twist Bioscience (TWST) over the last 5 years, with Sep 2024 value amounting to $293,000.

  • Twist Bioscience's Asset Writedowns and Impairment fell 80.89% to $293,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $940,000, marking a year-over-year decrease of 63.47%. This contributed to the annual value of -$20,000 for FY2025, which is 102.13% down from last year.
  • Per Twist Bioscience's latest filing, its Asset Writedowns and Impairment stood at $293,000 for Q3 2024, which was up 103.47% from $144,000 recorded in Q2 2024.
  • In the past 5 years, Twist Bioscience's Asset Writedowns and Impairment ranged from a high of $17.5 million in Q3 2022 and a low of -$1.0 million during Q2 2020.
  • For the 3-year period, Twist Bioscience's Asset Writedowns and Impairment averaged around $2.0 million, with its median value being $332,000 (2023).
  • Per our database at Business Quant, Twist Bioscience's Asset Writedowns and Impairment soared by 1,379.41% in 2022 and then tumbled by 91.26% in 2023.
  • Over the past 5 years, Twist Bioscience's Asset Writedowns and Impairment (Quarterly) stood at $248,000 in 2020, then soared by 373.39% to $1.2 million in 2021, then slumped by 78.36% to $254,000 in 2022, then dropped by 2.36% to $248,000 in 2023, then plummeted by 80.89% to $293,000 in 2024.
  • Its Asset Writedowns and Impairment was $293,000 in Q3 2024, compared to $144,000 in Q2 2024 and $255,000 in Q1 2024.